Edding Genor Completes Reverse Takeover Merger and Major Corporate Overhaul

Edding Genor Group Holdings Limited has completed a reverse takeover merger with a target company, issuing approximately 1.48 billion shares. The merger, effective December 30, 2025, follows shareholder approval and includes a corporate overhaul with a new name, logo, and governance changes. The company, formerly known as Genor Biopharma Holdings Limited, focuses on biopharmaceuticals and is listed on the Hong Kong Stock Exchange under stock code 6998. Current market cap is HK$1.61B, with a year-to-date price performance of 76.30%.